Clinical Research Directory
Browse clinical research sites, groups, and studies.
Semaglutide Treatment in Type 1 Diabetes
Sponsor: Nordsjaellands Hospital
Summary
The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabetes.
Official title: Obesity and Semaglutide in Type 1 Diabetes Therapy: A Multicentre, Randomised, Double-Blinded, Placebo-Controlled, Investigator-Initiated Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
122
Start Date
2025-10
Completion Date
2028-06
Last Updated
2025-08-08
Healthy Volunteers
No
Conditions
Interventions
Semaglutide 2.4mg
The active comparator of the intervention is s.c. Semaglutide injection once a week in increasing doses every month from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg and the placebo comparator is s.c. injection with a visually identical and same label pen as described for the active comparator
Semaglutide placebo
Visually identical and same label as the active comparator intervention
Locations (1)
Nordsjaellands Hospital
Hillerød, Denmark, Denmark